JPH02156962A - Medicine liberating device - Google Patents
Medicine liberating deviceInfo
- Publication number
- JPH02156962A JPH02156962A JP63313249A JP31324988A JPH02156962A JP H02156962 A JPH02156962 A JP H02156962A JP 63313249 A JP63313249 A JP 63313249A JP 31324988 A JP31324988 A JP 31324988A JP H02156962 A JPH02156962 A JP H02156962A
- Authority
- JP
- Japan
- Prior art keywords
- temperature
- medicine
- drug
- coil spring
- reservoir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 229940079593 drug Drugs 0.000 title claims description 48
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000012781 shape memory material Substances 0.000 claims description 3
- 230000009466 transformation Effects 0.000 abstract description 10
- 230000008602 contraction Effects 0.000 abstract description 4
- 229910000734 martensite Inorganic materials 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 description 15
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 8
- 230000036760 body temperature Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000009834 vaporization Methods 0.000 description 3
- 230000008016 vaporization Effects 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 239000013013 elastic material Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229910017773 Cu-Zn-Al Inorganic materials 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 229910004337 Ti-Ni Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229910011209 Ti—Ni Inorganic materials 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- KHYBPSFKEHXSLX-UHFFFAOYSA-N iminotitanium Chemical compound [Ti]=N KHYBPSFKEHXSLX-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008155 medical solution Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は患者を化学療法する場合等において体内に埋め
込んで使用される薬剤放出装置に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a drug release device that is implanted into the body and used when administering chemotherapy to a patient.
［従来の技術］
従来、患者の皮下部位に埋め込んだ皮下端子本体内に設
けたフレオン液を利用し、その皮下端子本体に設けたリ
ザーバからカテーテルを通じて薬液（抗癌剤等）を注出
して投与する体内埋込み式の薬剤放出装置が知られてい
る。この方式の薬剤放出装置では体温によってフレオン
液が温度上昇し、気化することによる圧力の上昇により
リザーバに貯溜した薬液がカテーテルを通じて体内の所
定部位に投与するようになっている。[Prior Art] Conventionally, a medical solution (anti-cancer drug, etc.) is injected and administered from a reservoir provided in the subcutaneous terminal body through a catheter using a Freon liquid provided in a subcutaneous terminal body implanted in the patient's subcutaneous site. Implantable drug delivery devices are known. In this type of drug delivery device, the temperature of the Freon liquid increases due to body temperature, and the pressure increases due to vaporization, so that the drug solution stored in the reservoir is administered to a predetermined site in the body through a catheter.
そして、この体内埋込み式の薬剤放出装置によれば、そ
の装置が体内に埋め込まれるため、カテーテル等が体外
に出ず、カテーテル等に由来する感染症の危険がないと
いうメリットの他、動力源の心配がない。また、入浴や
運動等の日常生活に及ぼす規制や制限が少ないという利
点がある。According to this implantable drug delivery device, since the device is implanted in the body, the catheter etc. do not come out of the body and there is no risk of infection caused by catheters etc. No worries. Another advantage is that there are fewer regulations and restrictions on daily life such as bathing and exercise.
［発明が解決しようとする課題］
しかしなから、この方式の薬剤放出装置ではフレオン液
の気化作用が重要なポイントであり、このため、その気
化による圧力を有効に利用できる微妙で複雑なフレオン
タンクや蛇腹構造を採用している。[Problem to be solved by the invention] However, the vaporization effect of the Freon liquid is an important point in this type of drug release device, and for this reason, a delicate and complicated Freon tank is required to effectively utilize the pressure caused by the vaporization. It uses a bellows structure.
このように従来の方式のものではその構造が複雑となり
、また、この結果、価格が高くなり、普及の妨げとなっ
ていた。As described above, the structure of the conventional type is complicated, and as a result, the price is high, which hinders its widespread use.
本発明は上記課題に着目してなされたもので、その目的
とするところは構成の簡略化が図れる体内埋込み型の薬
剤放出装置を提供することにある。The present invention has been made in view of the above problems, and its purpose is to provide an implantable drug release device that can be simplified in structure.
［課題を解決するための手段および作用］上記課題を解
決するために本発明の薬剤放出装置は、薬剤を貯留する
リザーバと、体表面側から生体に穿刺する薬剤注入用注
射針を刺通可能でその注射針を上記リザーバに通じる部
位まで刺入させるための弾性栓と、上記リザーバ内の体
積を変化させる送出用部材と、リザーバ内の温度の変化
により変形して上記送出用部材を付勢する形状記憶材料
からなる付勢部材と、上記リザーバ内の体積を変化によ
り吐出する薬剤を所望の体内部位に導く管路とから構成
したものである。[Means and effects for solving the problems] In order to solve the above problems, the drug release device of the present invention includes a reservoir for storing a drug and a drug injection needle that can be inserted into a living body from the body surface side. an elastic stopper for inserting the syringe needle to a portion communicating with the reservoir; a delivery member that changes the volume within the reservoir; and a delivery member that deforms due to temperature changes within the reservoir to bias the delivery member. The device is composed of a biasing member made of a shape-memory material, and a conduit that guides the medicine to be ejected by changing the volume within the reservoir to a desired intracorporeal site.
しかして、リザーバ内の温度の変化により変形する付勢
部材で上記送出用部材を付勢し、そのリザーバ内の体積
の変化により薬剤を送り出すことができる。また、上記
構成であるから、その構成の簡略化が図れる。Thus, the delivery member is urged by the urging member that deforms due to a change in temperature within the reservoir, and the drug can be delivered by changing the volume within the reservoir. Further, since the configuration is as described above, the configuration can be simplified.
［実施例］
第１図および第２図は本発明の第１の実施例を示すもの
である。この実施例の薬剤放出装置１は患者における皮
下部位に埋め込まれる。そして、この薬剤放出装置１の
本体２は生体適合性を有するプラスチック（例えばポリ
サルフォン）や金属（例えばチタン、チタン合金、５Ｕ
Ｓ３１６）等から形成され、その内部には後述する薬剤
室６を形成する空洞２ａを設けである。この本体２の空
洞２ａの上面体表面側開口部分にはやはり生体適合性を
有する弾性材料（例えばシリコン）からなる弾性栓３が
液密または気密的に固定されている。[Embodiment] FIGS. 1 and 2 show a first embodiment of the present invention. The drug release device 1 of this embodiment is implanted in a subcutaneous site in a patient. The main body 2 of this drug release device 1 is made of biocompatible plastic (e.g. polysulfone) or metal (e.g. titanium, titanium alloy, 5U
S316), etc., and a cavity 2a forming a drug chamber 6, which will be described later, is provided inside. An elastic plug 3 made of a biocompatible elastic material (for example, silicone) is fixed in a liquid-tight or air-tight manner to the opening on the upper surface side of the cavity 2a of the main body 2.
さらに、本体２の空洞２ａの下面側開口部分には同様に
生体適合性を有する弾性材料、例えばシリコン材料等か
らなる弾性膜４が張設されている。Furthermore, an elastic membrane 4 made of a biocompatible elastic material, such as a silicone material, is similarly stretched over the lower opening of the cavity 2a of the main body 2.
さらに、本体２の空洞２ａ内には上下方向にその内壁に
摺接して液密的または気密的に移動する送出用部材とし
てのプレート５が設けられている。Furthermore, a plate 5 is provided in the cavity 2a of the main body 2 as a delivery member that slides vertically against the inner wall thereof and moves in a liquid-tight or air-tight manner.
このプレート５は本体２の空洞２ａの内壁に対して液密
的または気密的に摺接させるため、その送出用プレート
らの周側面部にはＯリング等からなるシール部材９が装
着されている。In order to bring the plate 5 into liquid-tight or air-tight sliding contact with the inner wall of the cavity 2a of the main body 2, a sealing member 9 made of an O-ring or the like is attached to the peripheral side surface of the delivery plate. .
また、このプレート５で仕切る弾性体３側の密閉空間に
よってリザーバを構成する薬剤室６を形成している。こ
のリザーバとしての薬剤室６の内部には形状記憶合金か
らなる付勢部材としてのコイルばね７が設けられている
。すなわち、このコイルばね７は本体２の空洞２ａの上
壁部と上記プレート５の間に介装され、その各端は対応
する部材に対して取着されている。上記コイルばね７は
例えばＴｉ−Ｎｉ系合金、Ｃｕ−Ｚｎ−Ａｌ系合金等で
２方向性の記憶特性をもつ形状記憶記憶合金からから形
成されている。つまり、低温側では第２図で示すように
コイルばね７が伸長した形状になり、高温側では第１図
で示すようにコイルばね７が収縮した形状になるように
記憶させである。Further, the sealed space on the elastic body 3 side partitioned by the plate 5 forms a drug chamber 6 constituting a reservoir. A coil spring 7 as a biasing member made of a shape memory alloy is provided inside the drug chamber 6 as a reservoir. That is, this coil spring 7 is interposed between the upper wall of the cavity 2a of the main body 2 and the plate 5, and each end thereof is attached to a corresponding member. The coil spring 7 is made of a shape memory alloy having bidirectional memory characteristics, such as a Ti-Ni alloy or a Cu-Zn-Al alloy. That is, on the low temperature side, the coil spring 7 is stored in an expanded shape as shown in FIG. 2, and on the high temperature side, the coil spring 7 is stored in a contracted shape as shown in FIG.
そして、高温側から低温側へ移行する変ａ温度は、０℃
〜３０℃の温度範囲の中で設定し、低温側から高温側へ
移行する変態温度は、３５℃〜４０℃の温度の範囲の中
で設定する。Then, the variable a temperature that shifts from the high temperature side to the low temperature side is 0℃
The transformation temperature is set within the temperature range of 30°C to 30°C, and the transformation temperature for transition from the low temperature side to the high temperature side is set within the temperature range of 35°C to 40°C.
また、本体２の側面には上記薬剤室６に通じるカテーテ
ル８を導出している。このカテーテル８は生体の所望の
部位、例えば図示しない動脈や静脈に達してそれに挿入
固定するもので、薬剤室６からの薬剤を投与部位に導出
する管路を構成している。なお、図中１０は患者の体表
面である。Further, a catheter 8 leading to the drug chamber 6 is led out from the side surface of the main body 2. This catheter 8 is inserted into and fixed at a desired site of the living body, such as an artery or vein (not shown), and constitutes a conduit through which the drug from the drug chamber 6 is delivered to the administration site. In addition, 10 in the figure is the patient's body surface.
次に、このように構成された薬剤放出装置１の作用を説
明する。まず、第１図で示すごとく、この薬剤放出装置
１を生体に埋め込んで留置する。Next, the operation of the drug release device 1 configured as described above will be explained. First, as shown in FIG. 1, this drug release device 1 is implanted and left in a living body.
そして、薬剤室６に例えば抗癌剤、高カロリー輸液、イ
ンシュリン、ホルモン剤等の薬剤を補給する必要がある
場合、その薬剤を入れたシリンジ１１の注射針１１ａを
体表面１０からその皮膚部分を貫通して弾性栓３に刺し
入れる。この第１図で示す状態でシリンジ１１内の薬剤
をリザーバとしての薬剤室６内に注入する。このとき、
その薬剤はあらかじめ３０℃以下にしておくものとする
。When it is necessary to replenish the drug chamber 6 with a drug such as an anticancer drug, a high-calorie infusion, insulin, or a hormone, the injection needle 11a of the syringe 11 containing the drug is passed through the skin from the body surface 10. and insert it into the elastic stopper 3. In the state shown in FIG. 1, the drug in the syringe 11 is injected into the drug chamber 6 serving as a reservoir. At this time,
The chemical shall be kept at a temperature below 30°C in advance.
そして、この薬剤は注入する圧力により薬剤室６内に入
り込み、この薬剤室６内に設置されたコイルばね７に触
れる。この薬剤は３０℃以下の低温であるから、そのコ
イルばね７は低温側の状態になり、伸長する。そして、
この伸長に伴って、プレート５を押し下げ、第２図で示
すように薬剤室６の容積を増大させる。このため、薬剤
を取り込んで充分な量を貯留する。このとき、プレート
５が下がるに伴い、空洞２ａの底部空間にあった空気は
弾性膜４を押して伸長膨張させるため、ブレト５が下が
ることを妨げない。Then, the medicine enters into the medicine chamber 6 due to the injection pressure and comes into contact with the coil spring 7 installed inside the medicine chamber 6. Since this agent has a low temperature of 30° C. or lower, the coil spring 7 is in a low temperature state and expands. and,
Along with this extension, the plate 5 is pushed down and the volume of the drug chamber 6 is increased as shown in FIG. Therefore, the drug is taken in and stored in sufficient quantity. At this time, as the plate 5 is lowered, the air present in the bottom space of the cavity 2a pushes the elastic membrane 4 and causes it to expand and expand, so that it does not prevent the bullet 5 from lowering.
このように薬剤を充填した後、第２図で示す状態におい
て、体温により薬剤が徐々に温度上昇しはじめる。これ
と同時にコイルばね７の温度も上昇する。そして、高温
側の変態点に達すると、収縮を始める。このコイルばね
７は一端をプレート５に固定し、他端を本体２側に固定
しているため、その温度上昇に合わせてプレート５が上
昇し、薬剤室６の体積を減少させ、カテーテル８内へ薬
剤を送り込む。そして、このカテーテル８を通じて動脈
、静脈等、所望の体内器官に導かれる。ところで、体温
によるコイルばね７の温度上昇はゆるやかであり、この
上昇速度に合わせて、コイルばね７の収縮も徐々に動作
し、従って、薬剤は実質的に徐放されることになる。ま
た、放出速度を高めたい場合は、対応する体表面１０を
加温することで実現できる。なお、この実施例ではその
薬剤述する実施例のようにその一部を体の表面から露出
するように設置してもよい。After filling the drug in this manner, the temperature of the drug gradually begins to rise due to body temperature in the state shown in FIG. At the same time, the temperature of the coil spring 7 also rises. Then, when it reaches the transformation point on the high temperature side, it begins to shrink. Since this coil spring 7 has one end fixed to the plate 5 and the other end fixed to the main body 2 side, the plate 5 rises as the temperature rises, reducing the volume of the drug chamber 6 and causing the inside of the catheter 8 to rise. send drugs to. The catheter 8 is then guided to a desired internal organ such as an artery or vein. Incidentally, the temperature of the coil spring 7 rises slowly due to body temperature, and the contraction of the coil spring 7 gradually operates in accordance with this rising speed, so that the drug is substantially sustainedly released. Furthermore, if it is desired to increase the release rate, this can be achieved by heating the corresponding body surface 10. In addition, in this embodiment, the drug may be installed so that a part thereof is exposed from the surface of the body as in the embodiment described above.
第３図および第４図は本発明の第２の実施例を示すもの
である。この実施例では上記第１の実施例における２方
向性の形状記憶合金からなるコイルばねに代わりに１方
向性の形状記憶合金からなるコイルばね１２を使用した
ものである。この場合、コイルばね１２は高温側、例え
ば３５℃以上で収縮するようにその変態点を設定しであ
る。また、１方向性の形状記憶合金を使用するから、プ
レート５の下部にはバイアス用のコイルスプリング１３
の一端を固定し、コイルスプリング１３の他端は本体２
側に固定しである。また、このコイルスプリング１３は
上記形状記憶合金からなるコイルばね１２が低温側にあ
るとき、そのコイルばね１２を第４図のごとく伸展させ
るように収縮する構造に形成しである。3 and 4 show a second embodiment of the invention. In this embodiment, a coil spring 12 made of a unidirectional shape memory alloy is used instead of the coil spring made of a bidirectional shape memory alloy in the first embodiment. In this case, the transformation point of the coil spring 12 is set so that it contracts at a high temperature side, for example, 35° C. or higher. In addition, since a unidirectional shape memory alloy is used, a bias coil spring 13 is provided at the bottom of the plate 5.
One end of the coil spring 13 is fixed, and the other end of the coil spring 13 is fixed to the main body 2.
It is fixed on the side. Moreover, this coil spring 13 is formed in such a structure that when the coil spring 12 made of the shape memory alloy is on the low temperature side, it contracts so as to expand the coil spring 12 as shown in FIG.
しかして、生体内に埋入されている通常の状態では上記
コイルばね１２は体温と同温度になっており、第３図で
示すようにプレート５は上昇している。そこで、上述し
たと同様にシリンジ１１により薬剤を注入すると、その
コイルばね１２の温度が低下し、マルテンサイト相に変
態する。このため、バイアスコイル１３の収縮力が勝っ
て第４図で示すように薬剤室６を拡張する。このように
して薬剤室６に薬剤を充填することができる。In the normal state where the coil spring 12 is implanted in a living body, the temperature is the same as the body temperature, and the plate 5 is raised as shown in FIG. Therefore, when a drug is injected using the syringe 11 in the same manner as described above, the temperature of the coiled spring 12 decreases and transforms into a martensitic phase. Therefore, the contraction force of the bias coil 13 prevails and the drug chamber 6 is expanded as shown in FIG. In this way, the medicine chamber 6 can be filled with medicine.
そして、体温により薬剤の温度が上昇すると、これに伴
ってコイルばね１２の温度が変態点以上に上昇して収縮
を始める。これにより、プレート５が上昇して薬剤室６
を収縮させ、カテーテル８側に薬剤を送り出す。When the temperature of the medicine rises due to body temperature, the temperature of the coiled spring 12 rises above the transformation point and begins to contract. As a result, the plate 5 rises and the drug chamber 6
is contracted and the drug is delivered to the catheter 8 side.
第５図および第６図は本発明の第３の実施例を示すもの
である。この実施例では薬剤室６、コイルばね１２、バ
イアスコイル１３を横置きに設置し、バイアスコイル１
３側の部屋に連通して本体２に体外と空気が連通ずるフ
ィルタ１４と、このフィルタ１４を固定するリング１５
を固定しである。また、本体２の上部分は体表面１０を
貫通して露出するように設けてあり、その材質はハイド
ロキシアパタイト、β−ＴＣＰ、結晶化ガラス等のバイ
オアクティブなセラミック材からなり、皮膚組織と密着
結合するため、感染等の問題がない。5 and 6 show a third embodiment of the present invention. In this embodiment, the drug chamber 6, coil spring 12, and bias coil 13 are installed horizontally, and the bias coil 1
A filter 14 that communicates with the room on the third side and communicates air with the outside of the body in the main body 2, and a ring 15 that fixes this filter 14.
It is fixed. In addition, the upper part of the main body 2 is provided so as to penetrate through the body surface 10 and be exposed, and is made of a bioactive ceramic material such as hydroxyapatite, β-TCP, and crystallized glass, and is in close contact with the skin tissue. Because they are bonded together, there are no problems such as infection.
そして、この実施例は上述した第２の実施例と同じであ
るが、バイアスコイル１３の室側に体外とに連通部２ｂ
を設けであるため、第２の実施例で示すような弾性膜４
は不要である。This embodiment is the same as the second embodiment described above, but a communication portion 2b is provided between the chamber side of the bias coil 13 and the outside of the body.
Since the elastic membrane 4 as shown in the second embodiment is
is not necessary.
第７図は本発明の第４の実施例を示すものである。この
実施例ではコイルばね１２に通電加熱用の加熱電源１６
、加熱制御回路１７、スイッチ１８を本体２に設ける。FIG. 7 shows a fourth embodiment of the present invention. In this embodiment, a heating power source 16 for heating the coil spring 12 by energizing it.
, a heating control circuit 17, and a switch 18 are provided in the main body 2.
コイルばね１２は１方向性であり、その低温側、つまり
、体内温度においては第７図で示すようにバイアスコイ
ル１３の伸展力により、プレート５を介して収縮させら
れている。The coil spring 12 is unidirectional, and is contracted via the plate 5 by the expansion force of the bias coil 13 at the low temperature side, that is, at the internal body temperature, as shown in FIG.
そして、第７図で示す状態から腎コイルばね１２に必要
量の通電加熱を行なうことによって加熱し、記憶形状で
ある伸展状態に回復させ、プレート５をバイアスコイル
１３の力に抗して左側に移動させる。これにより薬剤室
６を収縮させて薬剤をカテーテル８側に供給する。Then, from the state shown in FIG. 7, the renal coil spring 12 is heated by applying a necessary amount of electrical current to restore it to the extended state, which is the memorized shape, and the plate 5 is moved to the left against the force of the bias coil 13. move it. This contracts the drug chamber 6 and supplies the drug to the catheter 8 side.
なお、本発明は上記各実施例のみに限定されるものでは
ない。例えば、形状記憶合金からなるコイルの加熱手段
としては第４の実施例以外にも、体外からマイクロウェ
ーブ、電熱線によるし−タ、誘導加温、超音波による加
熱、赤外線照射加熱等によるものでもよい。さらに、ま
た、形状記憶合金からなる付勢部材の変態点として変態
開始温度Ａｓと終了温度Ａｆがあり、その変態開始温度
Ａｓと終了温度Ａｆとの間の範囲で徐々に加熱温度を変
化させてもよく、このようにすれば、その温度の変化に
伴って形状を次第に変化させることができる。また、加
熱温度を断続的に変化させてもよい。Note that the present invention is not limited to the above embodiments. For example, as a heating means for a coil made of a shape memory alloy, in addition to the fourth embodiment, methods such as microwave heating from outside the body, heating using a heating wire, induction heating, heating using ultrasonic waves, infrared irradiation heating, etc. good. Furthermore, there are a transformation start temperature As and an end temperature Af as transformation points of the biasing member made of a shape memory alloy, and the heating temperature is gradually changed in the range between the transformation start temperature As and the end temperature Af. In this way, the shape can be gradually changed as the temperature changes. Further, the heating temperature may be changed intermittently.
また、第１、第２の実施例において、第４の実施例のご
とく加熱源を本体に設け、体外からの信号によりこの加
熱源を駆動させるテレメトリによる構成にしてもよい。Further, in the first and second embodiments, as in the fourth embodiment, a heating source may be provided in the main body, and the heating source may be driven by a signal from outside the body using telemetry.
また、送出用部材とこれを付勢する形状記憶材料からな
る付勢部材とを一体に構成するようにしてもよい。Further, the delivery member and a biasing member made of a shape memory material that biases the delivery member may be integrally configured.
［発明の効果］
以上説明したように本発明はリザーバ内の温度の変化に
より変形する付勢部材でリザーバ内の体積を変化させる
送出用部材を付勢し、そのリザーバ内の体積の変化によ
り薬剤を送り出すことができる構成であるから、その構
成の簡略化が図れる。[Effects of the Invention] As explained above, the present invention uses a biasing member that deforms due to a change in temperature within the reservoir to bias a delivery member that changes the volume within the reservoir, and the change in volume within the reservoir causes the drug to be released. Since the configuration is capable of sending out , the configuration can be simplified.
第１図および第２図は本発明の第１の実施例を示す概略
的な構成の説明図、第３図および第４図は本発明の第２
の実施例を示す概略的な構成の説明図、第５図および第
６図は本発明の第３の実施例を示す概略的な構成の説明
図、第７図は本発明の第４の実施例を示す概略的な構成
の説明図である。
１・・・薬剤放出装置、２・・・本体、３・・・弾性栓
、５・・・プレート、６・・・薬剤室、７・・・コイル
ばね、８・・・カテーテル、１１・・・シリンジ、１１
ａ・・・注射針、１３・・・バイアスコイル。
第１図1 and 2 are explanatory diagrams of a schematic configuration showing a first embodiment of the present invention, and FIGS. 3 and 4 are diagrams showing a second embodiment of the present invention.
FIG. 5 and FIG. 6 are explanatory diagrams of a schematic configuration showing a third embodiment of the present invention, and FIG. 7 is a diagram of a fourth embodiment of the present invention. FIG. 2 is an explanatory diagram of a schematic configuration showing an example. DESCRIPTION OF SYMBOLS 1... Drug release device, 2... Main body, 3... Elastic stopper, 5... Plate, 6... Drug chamber, 7... Coil spring, 8... Catheter, 11...・Syringe, 11
a... Syringe needle, 13... Bias coil. Figure 1
Claims (1)
剤を貯留するリザーバと、体表面側から生体に穿刺する
薬剤注入用注射針を刺通可能でその注射針を上記リザー
バに通じる部位まで刺入させるための弾性栓と、上記リ
ザーバ内の体積を変化させる送出用部材と、リザーバ内
の温度の変化により変形して上記送出用部材を付勢する
形状記憶材料からなる付勢部材と、上記リザーバ内の体
積を変化により吐出する薬剤を所望の体内部位に導く管
路とを具備してなることを特徴とする薬剤放出装置。A drug release device that is used by being implanted in the body includes a reservoir for storing the drug and a drug injection needle that can be inserted into the living body from the body surface side, and the needle is inserted to a site that communicates with the reservoir. a delivery member that changes the volume within the reservoir; a biasing member made of a shape memory material that deforms due to changes in temperature in the reservoir and biases the delivery member; 1. A drug release device comprising: a conduit that guides a drug ejected by changing the volume of the drug to a desired body site.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63313249A JPH02156962A (en) | 1988-12-12 | 1988-12-12 | Medicine liberating device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63313249A JPH02156962A (en) | 1988-12-12 | 1988-12-12 | Medicine liberating device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02156962A true JPH02156962A (en) | 1990-06-15 |
Family
ID=18038920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63313249A Pending JPH02156962A (en) | 1988-12-12 | 1988-12-12 | Medicine liberating device |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH02156962A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008543486A (en) * | 2005-06-23 | 2008-12-04 | ガンブロ・ルンディア・エービー | Implantable access device and method for preparing the same |
| JP2021514736A (en) * | 2018-02-26 | 2021-06-17 | プリモ メディカル グループ，インコーポレイテッド | Variable volume infusion port |
| US11678985B2 (en) | 2019-11-07 | 2023-06-20 | Primo Medical Group, Inc. | Systems, apparatus and methods to repair operation of a heart valve |
| US11697010B2 (en) | 2016-07-07 | 2023-07-11 | Primo Medical Group, Inc. | Septum for access port |
| US11801375B2 (en) | 2016-02-05 | 2023-10-31 | Primo Medical Group, Inc. | Access port locator and methods of use thereof |
-
1988
- 1988-12-12 JP JP63313249A patent/JPH02156962A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008543486A (en) * | 2005-06-23 | 2008-12-04 | ガンブロ・ルンディア・エービー | Implantable access device and method for preparing the same |
| US11801375B2 (en) | 2016-02-05 | 2023-10-31 | Primo Medical Group, Inc. | Access port locator and methods of use thereof |
| US11697010B2 (en) | 2016-07-07 | 2023-07-11 | Primo Medical Group, Inc. | Septum for access port |
| JP2021514736A (en) * | 2018-02-26 | 2021-06-17 | プリモ メディカル グループ，インコーポレイテッド | Variable volume infusion port |
| US11678985B2 (en) | 2019-11-07 | 2023-06-20 | Primo Medical Group, Inc. | Systems, apparatus and methods to repair operation of a heart valve |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11744937B2 (en) | Flexible and conformal patch pump | |
| AU2021225196B2 (en) | Infusion Of Drugs | |
| JP6616327B2 (en) | Fluid injection device | |
| EP2417991B1 (en) | Implantable infusion device | |
| US4699615A (en) | Finger actuated medication infusion system | |
| US6494867B1 (en) | Medical device | |
| EP1513580B1 (en) | Plunger assembly for patient infusion device | |
| US20040078028A1 (en) | Plunger assembly for patient infusion device | |
| EP0291510A4 (en) | Pressure regulated implantable infusion pump. | |
| US7601148B2 (en) | Infusion pump | |
| Ranade | Drug delivery systems 4. Implants in drug delivery | |
| US6464671B1 (en) | Medical system | |
| JPH02156962A (en) | Medicine liberating device | |
| KR102600940B1 (en) | Chamber unit for subcutaneous injection with drug storage and discharge function | |
| EP1189647B1 (en) | Implantable drug delivery system | |
| EP1173241B1 (en) | Implantable drug delivery system | |
| CN117836022A (en) | Drug delivery device with cannula with bioactive agent | |
| JPH03268766A (en) | Medical fluid injecting device |